Inhibitor of NF-κB activation, possibly via selective inhibition of LPS- and TNF-α-induced IκBα ubiquitination (IC50 = 3 μM). Blocks subsequent production of TNF-α, IL-1β and IL-6. Inhibits mucin production in an in vitro model of COPD, and is anti-inflammatory following oral administration in vivo. Also weakly inhibits EGFR, 5-lipoxygenase and iNOS. Purity 99%. MW (observed): 245.26